Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q2 2024 · 10-Q
Revenue$164.50M$164.50M+12.0% vs Q2 2023 Net Income-$18.64M-$18.64MN/M vs Q2 2023 EPS Diluted-$0.15-$0.15N/M vs Q2 2023 Gross Profit$72,494,000+21.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flowderived$13,892,000N/M Free Cash Flowderived$814,000N/M Margins · derivedGross margin44.1%+3.3 pt vs Q2 2023
Operating margin-13.3%+7.0 pt vs Q2 2023
Net margin-11.3%+5.2 pt vs Q2 2023
ended Jun 30, 2024 · filed Jul 30, 2024 · 30 d after period end